The mentally ill and cognitively disabled in prisons often are detained indefinitely
'When getting out?' Mr Faulton asks of anyone who will talk to him. He spends his hours pacing back and forth in his cell, periodically asphyxiating himself as a distraction from the blank horror of his days, squeezing his throat with his thumb and shutting off the airway. Most nights, his wailing resounds in the isolation wing.
When his mother visited him in prison, it was a heartbreaking scene as she wept and attempted to hold her son. When she departed, Adrian fell down on his hands and knees. sobbing and calling out for half an hour: 'go home, please, please'.
I believe this newspaper report to be the first – and still to date the only – contemporaneous, first-hand account in the media of the experience inside prison of a person unfit to plead subject to indefinite detention in this country. I later found out that Faulton had chewed one of his fingers off in prison.
The Northern Territory, which has one of the highest imprisonment rates in the world, is of course an outlier in its almost total lack of forensic healthcare facilities for prisoners such as Faulton, with an unknown number of cognitively disabled and severely mentally ill individuals housed in prison.
It was estimated in 2022 that the number of people with severe mental illness or cognitive disability, or both, who were detained indefinitely in the nation's prisons was about 1200 people nationwide, with documented examples of forensic patients being detained for up to 42 years and 30 years respectively in Queensland and the Northern Territory.
Extraordinarily, a federal parliamentary committee that investigated the issue couldn't gain clear statistics on this patient cohort – not even its real size, let alone any evidence beyond anecdote as to patients' experiences in detention, length of detention or rehabilitation outcomes. This underscores the fact our enormously expensive forensic justice systems are subject to little granular data collection, let alone scrutiny, in Australia. I would go so far as to say that, apart from some basic publicly accessible data, prisons are subject to the least transparency and scrutiny as to what really goes on in them of any major institution in this country.
To an observer like me, especially after having read this month the extraordinary personal reflection of forensic psychiatrist Trevor Ma in the journal Australasian Psychiatry, an absence of transparency generally in prisons leaves those valiantly attempting to provide care amid severe moral injury, fighting in the shadows. Ma painted a devastating picture of how Australia's carceral systems were making mentally ill people on the inside infinitely worse. Restrictive practices are the norm, including segregation of at times up to 24 hours a day, sometimes on and off for years. Effective treatments for those with psychotic disorders in the general prison system are simply widely unavailable.
Ma's stark observation that 'Australian prisons are places of punishment and fundamentally incompatible with good mental health' throws up a dilemma that seems to me to challenge directly the way our criminal justice system deals not only with the huge proportions of those with mental illness in prisons who receive little psychiatric care, but also the much smaller population that is unfit to plead.
When these individuals are placed on forensic orders, it's for a dual purpose: rehabilitation, but also the protection of the public. Politicians are justifiably concerned to protect public safety and most of those on forensic orders have been charged with extremely serious crimes. But I suspect if the public understood the circumstances of deprivation and disadvantage that affect many people with disability, who often end up in prison because of a failure of community healthcare, our discourse on these complex matters would be greatly enhanced.
Judges who issue forensic orders assume healthcare will be provided for these patients, ideally in a forensic hospital. But this doesn't always happen.
In NSW, the number of forensic patients in maximum security prison has been growing year on year as forensic hospitals overflow. The waiting list to get a bed in Sydney's main forensic hospital at Malabar frequently stretches to two years. Rehabilitation of mentally and cognitively impaired forensic patients in prison has been described by judges as an impossibility, and in fact the reverse occurs.
It's interesting to ponder how societies dealt with mentally ill and mentally disabled patients before the birth of psychiatry and the development of the common law that ushered in fitness to plead procedures. In pre-Norman England, before the development of the system of trial by jury after the Norman Conquest and the subsequent establishment of the King's Courts, those deemed insane were considered unable to form the necessary intention required for guilt, known as mens rea, and routinely were sent home to the care of their families rather than punished. Ancient Roman law also followed the principle of satis furore ipso puniter – living with madness is punishment enough for criminal behaviour.
As psychiatry advanced and understanding of mental illness became much more sophisticated, being deemed an idiot or madman was not sufficient to be excused from being held to possess the faculties necessary for a trial to proceed as long as a defendant could understand the trial process.
It was the case of James Hadfield in Victorian England, a member of a millennialist cult who attempted to bring about his own judicial execution via the botched shooting of King George III in 1800 at the Theatre Royal in Drury Lane, to bring about the Second Coming of Christ, that led to the enactment of the Criminal Lunatics Act in Britain.
The Criminal Lunatics Act mandated that those unfit to plead or not guilty by reason of insanity be sentenced to detention, predominantly in prisons or asylums. Treatment consisted of restraint and sedation akin to punishment. The finding of insanity required a diagnosis of a medical disorder. But what was delivered in asylums could hardly be said to be treatment. I would contend that it is arguably this lack of nexus between a medical diagnosis and a genuine medical treatment that still reverberates through justice health systems today when it comes to those unfit to plead.
Incarceration of those unfit to plead still does not come with any specific mandate under modern laws to provide treatment. This is especially so for the growing number of cognitively disabled people on forensic orders and in prisons generally. Cognitive disorders can be managed but cannot be rehabilitated. So how can our forensic systems be said to be at all fit for purpose?
When it comes to attempting to obtain liberty, the challenges for patients can be enormous. Even for those in forensic hospitals, it seems to me that the challenge for a patient of demonstrating at tribunal review hearings or in court that they no longer pose a risk to the public amounts to a Kafkaesque task – largely because remedial programs are so thin on the ground. Without access to such programs and demonstrated remediation, providing sufficient evidence to a risk-averse tribunal or judge in seeking a non-custodial order or release can be extremely difficult.
Barrister and academic Ian Freckelton has undertaken groundbreaking analysis of the reasoning of Supreme Court judges in Victoria who are tasked with hearing applications for release by forensic patients. In Victoria, the legislative threshold that must be satisfied of non-endangerment to the public has been held by judges to hinge on the achievement of stable mental health: in particular compliance with treatment and the substantial diminishment of symptoms or effective recovery. All of these factors are heavily influenced by the availability and effectiveness of mental health services within forensic detention systems. If these services are stretched so thin as we all know they are, here again is the catch-22 for patients. Not only that, judges also have tended to take into account the provision of services that would support a released patient in the community. Threadbare services here again come back to bite the patient: the state's neglect of community mental health could well mean the difference between incarceration and liberty.
In NSW, applications for release are decided by the Mental Health Review Tribunal. Unlike most mental health tribunals around Australia, hearings of the MHRT are open to the public in NSW. Yet, short of individuals attending to observe hearings, which is incredibly rare, we know virtually nothing from the public record about how the tribunal balances risk and liberty when hearing applications for release. Judgments are rarely published by the tribunal, ostensibly on the basis of identity protection.
Apart from a few key academic studies, we know little about how long patients spend in forensic detention – for instance, do they routinely spend longer in forensic detention than they would have if they had pleaded guilty to the crime of which they were charged?
So what is the risk of further crime on release? The literature in NSW shows that when forensic patients are able to access rehabilitation services, they pose a relatively low risk of recidivism when granted conditional and unconditional release. A 21-year retrospective outcome study by Sydney psychiatrist Olav Nielssen and his colleagues at the University of NSW found that reoffending by forensic patients released into the community in NSW was low and that none of the patients who were granted unconditional release in the 20 years up to 2010 went on to commit a further serious offence. Thomas Embling Hospital in Victoria has similar low recidivism rates for serious crime among those who have forensic orders revoked – in fact in 2021 that rate was zero.
When I've spoken to Nielssen about these findings, he has described them as one of the few bright spots on the mental illness policy horizon, in that it shows the forensic healthcare system is working and people are being rehabilitated. But could it be that if these patients had been provided with appropriate secure healthcare and social support outside of the justice system, the same low rates of recidivism would have been seen? Is this practical or affordable? I am not sure.
Certainly recidivism rates among those released from forensic orders are significantly lower than the general prison population. I do wonder, if we accept that those who have committed serious offences but are unfit to plead were very unwell or mentally impaired at the time of the offence, are we over-estimating the ongoing risk they pose if properly treated? Such treatment and the critical provision of secure housing are orders of magnitude cheaper to the state than forensic detention.
It is a sad reality even today that forensic patients are treated, in some instances, more harshly under the law than convicted prisoners. This has been starkly demonstrated in NSW by Kerri Eagle, a lawyer turned forensic psychiatrist, in her academic work analysing how the courts have dealt with forensic patients subject to limiting terms who face applications by the state for extensions to their forensic status. NSW imposes limiting terms – that is, a time-limited forensic order – for those who are unfit to plead who are found at a special hearing on the limited evidence available to have committed the crime for which they were charged. It's a qualified verdict of guilt but does not amount to a conviction. Amendments to the Mental Health (Forensic Provisions) Act in NSW legislate a test in similar terms to that applied to high-risk offenders subject to preventative detention orders – except that the legal threshold the state must meet to keep forensic patients in detention or subject to a custodial order, as opposed to, say, a recidivist pedophile, is far lower. Eagle has described this as 'unequal treatment under the law'. I think I'd describe it as flabbergasting.
Eagle's analysis found that almost all of the forensic patients whose cases she studied, most of them cognitively disabled but without mental illness, had remained in jail throughout their limiting terms and had not been transferred to a forensic hospital. This meant they effectively had received no rehabilitation or therapeutic care in the least restrictive environment possible. The trend was so stark that Eagle concluded these forensic patients were subject to ongoing loss of liberty by reason of a lack of access to appropriate care and treatment in prison. It hardly needs to be said that a prison environment for a cognitively disabled person is wholly inappropriate and amounts to punishing such individuals for something over which they have no control: their disability.
So what do we know about how forensic patients respond to their predicament and its profound uncertainty? In contrast to many aspects of healthcare and social service where experience rules the day, the experience of forensic patients is barely documented at all. Most of the academic studies of experience that have interviewed those in forensic detention internationally describe universal themes: patients experience a pervasive sense of resignation, fear, dread and anxiety daily. Patients are subject to conditions that in some instances are more restrictive than prison. They speak of living in fear of punishment, being subject to threats, violence, exertion of authority and living with a profound sense of disempowerment. Patients experience their situation in custody as being fixed and predetermined, and feel a sense of being 'stuck', with no power to influence their circumstances.
In conclusion, I want to return to the Northern Territory. After my visit to Berrimah prison in 2008, I was contacted by the guardian of a young Arrernte man, who told me that this young man was being held in maximum security prison in Alice Springs in horrendously harsh conditions and had been there for several years despite being unconvicted and cognitively disabled. Aged in his early 20s, the young man routinely would bang his head against the bars of his cell until he bled. He was shackled every time he stepped out of his cell, routinely forcibly sedated, and on several occasions placed in a spit hood and strapped to a restraint chair. Tragically, this young disabled man had fatally stabbed his uncle, whom he dearly loved, as a teenager after being left alone and unsupervised all day in a remote community. I followed this man's story for more than 15 years and late last year was able to report on his eventual freedom after 17 years in the forensic system. The NT government had fought tooth and nail for the continuation of forensic orders, but the NT Supreme Court was swayed by the fact, with the right care, with National Disability Insurance Scheme and family support, this young man displayed an enormous reduction in behaviours of concern and was a largely peaceful citizen. Sadly, I cannot name this man now because in May he died at the age of just 34, after less than a year of freedom. He spent almost as many years of his life locked in prison as he did free.
But his fight for freedom set an important precedent. The headline of our story of this man's eventual, cruelly short freedom, was: Imprisoned by Disability. His case was extreme, but that headline would seem to me to apply to many forensic patients, even those in forensic hospitals. The key question for me in these matters is: amid an appalling lack of mental healthcare and in the enormous challenges of caring for those charged with awful crimes but not criminally culpable, are we really mitigating risk or are we amplifying it? And at what cost?
This is an edited text of Natasha Robinson's speech to the Royal Australian and New Zealand College of Psychiatrists Forensic Faculty Conference in Melbourne. Robinson, The Australian's health editor, is an admitted lawyer and a doctoral candidate at QUT's Australian Centre for Health Law, researching forensic mental health law.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

News.com.au
9 hours ago
- News.com.au
Deadly honeybee parasite varroa mites detected in Gippsland, Victoria beehives
A deadly parasite that infests beehives and kills honey bees has spread through regional Victoria. Varroa mites have been detected in beehives throughout the Gippsland region, putting apiarists on alert to monitor their hives for any infestation. Gippsland Apiarist Association president Stan Glowacki said once a mite got into a beehive it could build up numbers where it killed off the hive within about six to nine months. 'If you have 400 hives that could be quite a financial hit to your operation,' he said. 'It's going to affect every beekeeper, it does not matter whether they have one hive or 1000 hives.' Varroa destructors are a parasite of adult honey bees and broods that weaken and kill honey bee colonies and transmit viruses, according to Victoria Agriculture. They are a major problem for commercial and hobby beekeepers once they become established. Varroa mites were first detected in NSW in June 2022. A national eradication response saw 14,000 hives euthanised before it was determined it was not feasible to achieve total elimination. Authorities and beekeepers now manage the pest, which can cost about $40 a year per hive, according to Mr Glowacki. 'It's a little parasitic mite that moves on the bees,' Mr Glowacki said. 'To scale it up to human size, it's the equivalent of having a parasite the size of a dinner plate stuck on your body, sucking out your blood.' He said once a female mite got inside a hive and a brood hatched it was an exponential threat. 'It's very worrying even for a small backyard beekeeper. Nobody wants to lose their bees,' he said. 'If you don't monitor your hives and manage the mite you're going to lose your hives. 'Eventually we're going to get to the stage where the industry is going to know the genetics and have hives that can manage the mite without the use of chemicals. 'But until we get to that stage people will lose hives and pay for the chemicals to try and keep their hives alive.'

News.com.au
11 hours ago
- News.com.au
Scott Power: ASX health stocks up in ‘reasonable start' to reporting season
ASX heath sector up 2.33% over past five days, while broader markets ros 1.2% Avita downgrades FY25 guidance and announces $23 million capital raise 'Materially undervalued' CSL due to report FY25 results next week Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gives his take on the ASX healthcare sector for the week and his 'Powerplay' stock pick. The ASX Health Care Index (ASX:XHJ) has risen 2.33% for the past five days, beating the benchmark S&P/ASX 200 (ASX:XJO) up 1.2% for the same period in what Morgans' senior healthcare analyst Scott Power has described as a "reasonable start" to reporting season. In the large caps, US-focused radiology imaging house Pro Medicus (ASX:PME) jumped ~6% on Thursday after releasing its FY25 results, which co-founder and CEO Dr Sam Hupert dubbed 'the most successful year in the company's history by any measure'. Pro Medicus revenue for FY25 was up 32% to $213 million with underlying profit before tax rising 40.2% to $163.3m and net profit up 39.2% to $115.2m. The company achieved a record year for contract wins, renewals, and additional module sales. Cash and financial assets grew 35.5% to $210.7m, with ProMedicus remaining debt-free. A fully-franked final dividend of 30 cents per share was declared. Morgans maintains a trim rating on Pro Medicus and has raised its 12-month target price to $285 from $280. A favourite among investors Pro Medicus is trading above that target at around $315. "Pro Medicus reported a result in line with our expectations and the share price responded positively up with strong earnings growth forecast for FY26," Power said. However, investors in Cochlear (ASX:COH) weren't tuning in to quite as positive news. The global hearing implant leader's FY25 results released today came in below expectations and its price fell ~2%. Cochlear reported FY25 NPAT of $392m, which was slightly below consensus of $400m but within recently downgraded guidance of A$390–400m. Revenue rose 4% to $2.356 billion, also slightly under expectations. Cochlear implants sales grew 12% to 53,968 units, slightly above consensus, driven by early access to the new Nucleus Nexa system in the EU and APAC. Developed markets grew 6%, below expectations, while emerging markets surged over 20%. Services revenue, which accounts for ~25% of total revenue declined 9% to $609m, impacted by slower uptake of the N8 sound processor launched in 2023 with US "cost of living" pressures flagged as a factor delaying the replacement cycle. The interim dividend was $2.15, beating forecasts. Cochlear has provided NPAT guidance of $435m to $460m for FY26, slightly below consensus of $461m with Morgans forecasting $436m. Avita bandages up after 'poor' Q2 result Dual Nasdaq-listed wounds management house Avita Medical (ASX:AVH) posted what Morgans' healthcare analyst Iain Wilkie described as a "poor result" for Q2 CY25 and also announced a $22m capital raise. Full-year 2025 revenue guidance was downgraded to a range of $76m to $81m compared to previous guidance of $100m to $106m, reflecting growth of ~19% to 27% over full-year 2024 revenue. Avita revenue for Q2 CY25 of US$18.4m was flat QoQ, and up 21% YoY as demand for its flagship spray-on skin treatment Recell fell ~20% due to unresolved reimbursement issues with medicare administrative contractors (MACs) in the US. Net loss for Q2 improved to US$9.9m, down from US$15.4m on pcp but according to Wilkie was "still insufficient to ease near-term cash flow concerns". In a note to clients Wilkie wrote Avita must deliver US$20m per quarter in H2 CY25 to meet the lower end of guidance. Profitability timelines have now also been pushed, with cash flow breakeven expected in Q2 CY26 and GAAP profitability expected in Q3 26, both delayed by one year. "A poor result, and confirms a structural delay in its breakeven trajectory, but we don't see this as a structural derailment," he wrote. "Commentary around resolutions made in July as Medicare contractors initiate pricing and payments is a good sign this is reversing. "Still, hard for investors to stomach yet another downgrade to guidance. He said the key takeaway with Avita's latest results was the US payor system was complicated. Meanwhile, answering concerns about its balance sheet Avita announced on Wednesday a $23m equity raising, by way of a private placement at $1.32 per share, an 11% discount on the previous close. Although capital raising often drags on a share price, Avita's stock jumped as much as 13% as investors welcomed the added breathing room. Morgans maintains a speculative buy on Avita but has downgraded its 12-month price target from $3.78 to $2. EBR's WiSE finds its rhythm with early sales Developer of the WiSE CRT System – the world's only leadless solution for pacing the left side of the heart, EBR Systems (ASX:EBR) has released its Q2 CY25 results, which was largely in line with expectations – per Morgans healthcare analyst Derek Jellinek in a note to clients. Cash burn was down US$2m to US$11.5m, mainly on lower R&D spend with US$87m cash on hand, which Jellinek wrote was adequate funding for more than seven quarters at the current rate. "Notably, June saw ~US$150k in first commercial sales from three WiSE CRT devices across two leading US hospitals, with favourable physician and patient feedback increasing despite no reimbursement, which is still expected later this year," Jellinek wrote. "We continue to view the phased US commercial rollout, with limited market release in Q4 CY25 followed by full commercial launch in CY26, as prudent, balancing adoption with execution quality." EBR was granted US Food and Drug Administration (FDA) approval for the launch of its Wise CRT system in the US in April. Morgans maintains a buy rating on EBR with a 12-month price target of $2.86. Tetratherix gets government grant for manufacturing facility Newly locally listed wound management company Tetratherix (ASX:TTX) has been awarded $3.3m non-dilutive grant from the Australian government's Industry Growth Program to co-fund its manufacturing facility expansion. The funding will be spread across FY26 and FY27 with Tetratherix contributing to the balance of $4m. Following its ASX debut on June 30, the company allocated $10.2m from its IPO funds for manufacturing expansion. The expanded manufacturing will enable the supply of product for the bone regeneration franchise which is on target for US FDA clearance in H2 CY 26. Power said other upcoming catalysts for Tetratherix include a master service agreement executed with an orthopaedic company expected in H1 CY26. An update on recruitment in a pivotal trial for cohort two using its tissue healing product TetraDerm involving surgical incisions in face/neck is also expected also in the H1 CY26. "Its clearly positive news for Tetratherix and we will assume that the saving in manufacturing will be re-allocated to funding other franchises including bone regeneration, tissue spacing, tissue healing," Power said. "TTX's share price is up over 40% since the IPO and we expect the cadence of news flow to maintain investor interest over the coming quarters." Power's Powerplay: 'Materially undervalued' CSL to report FY25 results The ASX's largest healthcare company, CSL (ASX:CSL) is Power's pick of the week, with the blood products giant due to report its FY25 results next Tuesday. In a July note to clients Power's colleague Jellinek wrote that CSL was currently trading at levels significantly below fair value, pricing it as less than a single-division company, with the main Behring division alone justifying a higher valuation and no value assigned to either Seqirus or Vifor. Morgans 'view CSL as materially undervalued' and over the past decade the company had averaged an EV/EBIT multiple of 24.7 times but today it sits at 18.2 times. Strong demand and cost-cutting measures have helped margins recover for CSL Behring, which focuses on rare and serious diseases such as bleeding and immune disorders and made up more than 70% of earnings. Morgans noted CSL's flu vaccines business Seqirus faced short-term uncertainty around vaccine uptake and the impact of vaccine skeptic Robert F Kennedy Jr's position as Health secretary, but demand was still supported by pandemic contracts. Growth in CSL's iron deficiency and kidney care business Vifor, while slower than expected was also showing signs of improvement. "Combined, we estimate an intrinsic value of $196 bn, representing c35% upside from current trading levels," Jellinek wrote. Morgans has a buy rating on CSL and 12-month target price of $303.70. The views, information, or opinions expressed in the interview in this article are solely those of the interviewee and do not represent the views of Stockhead. Stockhead has not provided, endorsed or otherwise assumed responsibility for any financial product advice contained in this article. At Stockhead, we tell it like it is. While EBR Systems is a Stockhead advertiser, the company did not sponsor this article.

ABC News
11 hours ago
- ABC News
Tasmania looks to fast-track new antibiotic for farmed salmon as bacterial disease continues to spread
The Tasmanian government is seeking fast-tracked approval for another antibiotic to be used to treat farmed salmon in public waterways as it continues to grapple with an endemic bacterial disease. Piscirickettsia salmonis — or P. salmonis — is continuing to circulate in salmon pens in southern Tasmania after a mass mortality event in the summer, with fears over warmer winter and spring conditions. Crossbench MPs were briefed on Friday, and claim that the urgency was due to a worsening outbreak in at least one part of the D'Entrecasteaux Channel, which they say was confirmed under questioning during the briefing. The government has avoided using the term "outbreak", instead describing the disease as "endemic" in multiple regions and that mortalities have not reached reportable levels at this stage. Farmed salmon were treated with an oxytetracycline antibiotic during the summer outbreak, when globules of fat from dead fish washed up on multiple beaches. The industry is now pushing for the use of an antibiotic called Florfenicol — which would require new approvals — and has been engaging with the government since February. Primary Industries Minister Gavin Pearce said oxytetracycline had "limited uses" and that he wanted to push ahead with Florfenicol. "This is not listed on Australian labels and approved, however, that process is going forward with the authority at the moment," Mr Pearce said. "We're looking at probably four to six weeks by the time we get an interim permit for that use. Tasmania's Natural Resources and Environment Department confirmed that compliance and intelligence gathering was occurring over farmed fish pens in southern Tasmania, to monitor any increased mortalities. Acting chief veterinary officer Deborah McSweyn said the new antibiotic would be administered as a top coat feed, which could spread into the surrounding marine environment. "There is absolutely every chance that it will spread beyond the pens," she said. "That is why we collaborate with the EPA [Environmental Protection Authority] to do really robust and very rigorous testing to monitor those effects." The EPA is developing a monitoring schedule for Florfenicol to determine how it spreads into the marine environment once administered for farmed fish. The EPA publishes monitoring reports online, but does not disclose when antibiotic use begins, leaving it up to salmon companies to disclose. The extent of current fish mortalities has not been publicly released. Under Tasmanian regulations, mortality events are only reported if more than 0.25 per cent of fish die in a pen over three consecutive days. Independent Franklin MP Peter George told ABC Radio Hobart that Premier Jeremy Rockliff contacted him on Thursday night — before the briefing — to disclose concerns about the level of disease in a pen. Ms McSweyn said the level of disease in pens was "very hard to know". "P. salmonis will always be there as an endemic bacteria. "There is no way of being clear of P. salmonis." She said there had not been an increase in antibiotic resistance among farmed salmon, and that testing for this was continuing. When asked if salmon with P. salmonis was continuing to be harvested for human consumption, Ms McSweyn said the disease was endemic. The Natural Resources and Environment Department previously said the bacterium does not pose a risk to human health. Four crossbench MPs — Greens leader Rosalie Woodruff, and independents Mr George, Craig Garland and Kristie Johnston — attended the briefing with agency officials. They were concerned about whether the government had been able to obtain all relevant information from salmon companies over the extent of disease levels and mortalities. Mr George said the industry needed greater reporting conditions over disease spread. "What was made less clear today is exactly the extent of the disease outbreak, and that's because the … multinational fish farms do not have to tell anyone about the extent of the disease," he said. The crossbenchers remain in negotiations with the Liberals and Labor ahead of a no-confidence motion on Tuesday to determine the next premier and government, and again called for greater regulations for the salmon industry. When asked if the ongoing and evolving use of antibiotics was sustainable for the farmed salmon industry, Mr Pearce said it was common in agricultural sectors. "In my humble opinion, science continues to evolve every day," he said. "If I took you back 10 years, most of the antibiotics [and] medication that you would have been prescribed 10 years ago is no longer available." In a statement, industry body Salmon Tasmania said intended new treatments would form part of a range of actions to combat P. salmonis. "New actions include improved vaccines, stronger biosecurity, feed adjustments, on-farm innovations, and new treatment options," the statement reads.